These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

534 related items for PubMed ID: 19359333

  • 1. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population.
    Cowie MR, Marshall D, Drummond M, Ferko N, Maschio M, Ekman M, de Roy L, Heidbuchel H, Verboven Y, Braunschweig F, Linde C, Boriani G.
    Europace; 2009 Jun; 11(6):716-26. PubMed ID: 19359333
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of implantable cardioverter-defibrillators.
    Sanders GD, Hlatky MA, Owens DK.
    N Engl J Med; 2005 Oct 06; 353(14):1471-80. PubMed ID: 16207849
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of cardioverter-defibrillators in heart failure patients.
    Gandjour A.
    Europace; 2009 Dec 06; 11(12):1721. PubMed ID: 19880854
    [No Abstract] [Full Text] [Related]

  • 4. Pitfalls in health-economic evaluations: the case of cost-effectiveness of prophylactic implantable cardioverter-defibrillator therapy in Belgium.
    Van Brabandt H, Neyt M.
    Europace; 2009 Dec 06; 11(12):1571-3. PubMed ID: 19819879
    [No Abstract] [Full Text] [Related]

  • 5. The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis.
    Smith T, Jordaens L, Theuns DA, van Dessel PF, Wilde AA, Hunink MG.
    Eur Heart J; 2013 Jan 06; 34(3):211-9. PubMed ID: 22584647
    [Abstract] [Full Text] [Related]

  • 6. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
    Yao G, Freemantle N, Calvert MJ, Bryan S, Daubert JC, Cleland JG.
    Eur Heart J; 2007 Jan 06; 28(1):42-51. PubMed ID: 17110403
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population.
    Chan PS, Stein K, Chow T, Fendrick M, Bigger JT, Vijan S.
    J Am Coll Cardiol; 2006 Jul 04; 48(1):112-21. PubMed ID: 16814657
    [Abstract] [Full Text] [Related]

  • 8. Response to editorial: Pitfalls in economic analysis.
    Cowie MR.
    Europace; 2010 Jul 04; 12(7):1044-6; author reply 1046-7. PubMed ID: 20478929
    [No Abstract] [Full Text] [Related]

  • 9. Is combined resynchronisation and implantable defibrillator therapy a cost-effective option for left ventricular dysfunction?
    Bond M, Mealing S, Anderson R, Dean J, Stein K, Taylor RS.
    Int J Cardiol; 2009 Nov 12; 137(3):206-15. PubMed ID: 18703244
    [Abstract] [Full Text] [Related]

  • 10. Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention.
    Chan PS, Nallamothu BK, Spertus JA, Masoudi FA, Bartone C, Kereiakes DJ, Chow T.
    Circ Cardiovasc Qual Outcomes; 2009 Jan 12; 2(1):16-24. PubMed ID: 20031808
    [Abstract] [Full Text] [Related]

  • 11. Microvolt T-wave alternans and the selective use of implantable cardioverter defibrillators for primary prevention: a cost-effectiveness study.
    Filion KB, Xie X, van der Avoort CJ, Dendukuri N, Brophy JM.
    Int J Technol Assess Health Care; 2009 Apr 12; 25(2):151-60. PubMed ID: 19331707
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age.
    Sanders GD, Kong MH, Al-Khatib SM, Peterson ED.
    Am Heart J; 2010 Jul 12; 160(1):122-31. PubMed ID: 20598982
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
    Mark DB, Nelson CL, Anstrom KJ, Al-Khatib SM, Tsiatis AA, Cowper PA, Clapp-Channing NE, Davidson-Ray L, Poole JE, Johnson G, Anderson J, Lee KL, Bardy GH, SCD-HeFT Investigators.
    Circulation; 2006 Jul 11; 114(2):135-42. PubMed ID: 16818817
    [Abstract] [Full Text] [Related]

  • 14. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy.
    You JJ, Woo A, Ko DT, Cameron DA, Mihailovic A, Krahn M.
    Am Heart J; 2007 Nov 11; 154(5):899-907. PubMed ID: 17967596
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of primary prevention implantable cardioverter defibrillator treatment: data from a large clinical registry.
    Thijssen J, van den Akker van Marle ME, Borleffs CJ, van Rees JB, de Bie MK, van der Velde ET, van Erven L, Schalij MJ.
    Pacing Clin Electrophysiol; 2014 Jan 11; 37(1):25-34. PubMed ID: 23998638
    [Abstract] [Full Text] [Related]

  • 16. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
    Buxton M, Caine N, Chase D, Connelly D, Grace A, Jackson C, Parkes J, Sharples L.
    Health Technol Assess; 2006 Aug 11; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
    [Abstract] [Full Text] [Related]

  • 17. The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II.
    Zwanziger J, Hall WJ, Dick AW, Zhao H, Mushlin AI, Hahn RM, Wang H, Andrews ML, Mooney C, Wang H, Moss AJ.
    J Am Coll Cardiol; 2006 Jun 06; 47(11):2310-8. PubMed ID: 16750701
    [Abstract] [Full Text] [Related]

  • 18. Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy.
    Huang DT, Sesselberg HW, McNitt S, Noyes K, Andrews ML, Hall WJ, Dick A, Daubert JP, Zareba W, Moss AJ, MADIT-II Research Group.
    J Cardiovasc Electrophysiol; 2007 Aug 06; 18(8):833-8. PubMed ID: 17537209
    [Abstract] [Full Text] [Related]

  • 19. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
    Pradelli L, Iannazzo S, Zaniolo O.
    Am J Cardiovasc Drugs; 2009 Aug 06; 9(6):383-92. PubMed ID: 19929036
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction).
    Linde C, Mealing S, Hawkins N, Eaton J, Brown B, Daubert JC, REVERSE study group.
    Eur Heart J; 2011 Jul 06; 32(13):1631-9. PubMed ID: 21112898
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.